From: Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal
Ref | Country | City | Year | Patients | Methods | CAM | MNZ | LVX | TCN | AMX | Others |
---|---|---|---|---|---|---|---|---|---|---|---|
[22] | India | Gujarat | 2008–2011 | 80 | DDM | 58.8 % | 83.8 % | 72.5 % | 53.8 % | 72.5 % | Ciprofloxacin (50 %) |
[33] | India | Multicentre | – | 259 | E-test | 44.7 % | 77.9 % | – | – | 32.8 % | – |
[53] | India | Kolkata | 2000–2001 | 67 | ADM | 0.0 % | 85.1 % | – | 7.5 % | 0.0 % | Furazolidone (0.0 %) |
[37] | India | North India | – | 68 | ADM | 11.8 % | 48.5 % | – | 16.2 % | 17.6 % | Furazolidone (22.1 %) |
[34] | India | Varanasi | 2005–2006 | 63 | ADM | 4.7 % | 100.0 |  | 0.0 % | 65.1 % | – |
[32] | Pakistan | Karachi | 2005–2008 | 178 | NM | 36.0 % | 89.0 % | – | 12.0 % | 37.0 % | Ofloxacin (18.5 %) |
[54] | Pakistan | Karachi | 2008–2013 | 92 | E-test | 5.4 % | 97.8 % | 16.2 % | 4.3 % | 2.2 % | Ofloxacin (30.1 %), Furazolidone (15.2 %) |
[55] | Pakistan | Karachi | 2007–2009 | 92 | E-test | 32.6 % | 47.8 % | – | – | 2.2 % | – |
[56] | Pakistan | Karachi | 2009–2010 | 162 | E-test | 37.0 % | – | – | – | – | Fluoroquinolone 62.3 % |
[35] | Pakistan | Rawalpindi | 2011–2012 | 46 | E-test | 47.8 % | 73.9 % | – | 4.4 % | 54.3 % | Ciprofloxacin (13.0 %) |
[57] | Bangladesh | Dhaka | 1999–2001 | 174 | ADM | 10.0 % | 77.5 % | – | 15.0 % | 6.6 % | – |
[23] | Bangladesh | Dhaka | 2014 | 56 | ADM | 39.3 % | 94.6 % | 66.1 % | 0.0 % | 3.6 % | – |